Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Edesa Biotech, Inc. before investing.

In this article, we go over a few key elements for understanding Edesa Biotech, Inc.’s stock price such as:

• Edesa Biotech, Inc.’s current stock price and volume
• Why Edesa Biotech, Inc.’s stock price changed recently
• Upgrades and downgrades for EDSA from analysts
• EDSA’s stock price momentum as measured by its relative strength

About Edesa Biotech, Inc. (EDSA)

Before we jump into Edesa Biotech, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Want to learn more about Edesa Biotech, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Edesa Biotech, Inc..

What Caused Edesa Biotech, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 29, 2026, there were analysts who downgraded Edesa Biotech, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Edesa Biotech, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Edesa Biotech, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Edesa Biotech, Inc. (EDSA) by visiting AAII Stock Evaluator.

Relative Price Strength of Edesa Biotech, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 29, 2026, Edesa Biotech, Inc. has a weighted four-quarter relative price strength of 76.82%, which translates to a Momentum Score of 99 and is considered to be Very Strong.

Want to learn more about how Edesa Biotech, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Edesa Biotech, Inc. Stock Price: Bottom Line

As of June 1, 2026, Edesa Biotech, Inc.’s stock price is $6.690, which is down 7.34% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Edesa Biotech, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.